Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Clare Bailey

Showing results (51-60 of 91) with videos related to

Pageof 10
Sort By:
Eye (London, England)|January 16, 2026
Infographic: SPECTRUM: study design of the global real-world study of aflibercept 8 mg in the treatment of neovascular age-related macular degeneration and diabetic macular edemaClare Bailey, Clemens Lange, Marion R Munk, et al.
Eye (London, England)|October 7, 2022
Practical implementation of a q4-q16 aflibercept treat-and-extend pathway for the treatment of neovascular age-related macular degeneration: Updated guidance from a UK expert panelClare Bailey, Peter Cackett, Ajay Kotagiri, et al.
Clinical Trials (London, England)|August 31, 2025
Automated data collection from an electronic medical record for a prospective real-world study in patients with retinal disease (VOYAGER)Clare Bailey, Ian Pearce, Christiana Dinah, et al.
Eye (London, England)|December 24, 2024
2-year results from an observational study of proactive treatment regimens with intravitreal aflibercept 2 mg in patients with nAMD in clinical practice: XTEND study UK cohortClare Bailey, Manju Chandran, Richard Gale, et al.
Eye (London, England)|August 30, 2024
Dual pathway inhibition with faricimab for previously treated neovascular age-related macular degeneration and diabetic macular oedema: guidance from a UK panel of retina specialistsLouise Downey, Sobha Sivaprasad, Ramandeep Chhabra, et al.
Translational Vision Science & Technology|May 18, 2021
Reliability of Retinal Pathology Quantification in Age-Related Macular Degeneration: Implications for Clinical Trials and Machine Learning ApplicationsPhilipp L Müller, Bart Liefers, Tim Treis, et al.
Clinical Ophthalmology (Auckland, N.Z.)|November 8, 2024
Expert Panel Consensus for Optimizing Outcomes in Neovascular Age-Related Macular Degeneration in the Context of Suboptimal Response to a Biosimilar: The Role of AfliberceptNirodhini Narendran, Clare Bailey, Louise Downey, et al.
BMJ (Clinical Research Ed.)|June 12, 2010
Bevacizumab for neovascular age related macular degeneration (ABC Trial): multicentre randomised double masked studyAdnan Tufail, Praveen J Patel, Catherine Egan, et al.
Philosophical Transactions. Series A, Mathematical, Physical, and Engineering Sciences|September 16, 2006
Designing solution-processable air-stable liquid crystalline crosslinkable semiconductorsIain McCulloch, Clare Bailey, Kristijonas Genevicius, et al.
Current Medical Research and Opinion|May 30, 2024
Real-world service costs for neovascular-AMD clinics in the United Kingdom: structured literature review and scenario analysisSobha Sivaprasad, Clare Bailey, Louise Downey, et al.
Pageof 10

Showing results (51-60 of 91) with videos related to

Sort By:
Pageof 10
Eye (London, England)|January 16, 2026
Infographic: SPECTRUM: study design of the global real-world study of aflibercept 8 mg in the treatment of neovascular age-related macular degeneration and diabetic macular edemaClare Bailey, Clemens Lange, Marion R Munk, et al.
Eye (London, England)|October 7, 2022
Practical implementation of a q4-q16 aflibercept treat-and-extend pathway for the treatment of neovascular age-related macular degeneration: Updated guidance from a UK expert panelClare Bailey, Peter Cackett, Ajay Kotagiri, et al.
Clinical Trials (London, England)|August 31, 2025
Automated data collection from an electronic medical record for a prospective real-world study in patients with retinal disease (VOYAGER)Clare Bailey, Ian Pearce, Christiana Dinah, et al.
Eye (London, England)|December 24, 2024
2-year results from an observational study of proactive treatment regimens with intravitreal aflibercept 2 mg in patients with nAMD in clinical practice: XTEND study UK cohortClare Bailey, Manju Chandran, Richard Gale, et al.
Eye (London, England)|August 30, 2024
Dual pathway inhibition with faricimab for previously treated neovascular age-related macular degeneration and diabetic macular oedema: guidance from a UK panel of retina specialistsLouise Downey, Sobha Sivaprasad, Ramandeep Chhabra, et al.
Translational Vision Science & Technology|May 18, 2021
Reliability of Retinal Pathology Quantification in Age-Related Macular Degeneration: Implications for Clinical Trials and Machine Learning ApplicationsPhilipp L Müller, Bart Liefers, Tim Treis, et al.
Clinical Ophthalmology (Auckland, N.Z.)|November 8, 2024
Expert Panel Consensus for Optimizing Outcomes in Neovascular Age-Related Macular Degeneration in the Context of Suboptimal Response to a Biosimilar: The Role of AfliberceptNirodhini Narendran, Clare Bailey, Louise Downey, et al.
BMJ (Clinical Research Ed.)|June 12, 2010
Bevacizumab for neovascular age related macular degeneration (ABC Trial): multicentre randomised double masked studyAdnan Tufail, Praveen J Patel, Catherine Egan, et al.
Philosophical Transactions. Series A, Mathematical, Physical, and Engineering Sciences|September 16, 2006
Designing solution-processable air-stable liquid crystalline crosslinkable semiconductorsIain McCulloch, Clare Bailey, Kristijonas Genevicius, et al.
Current Medical Research and Opinion|May 30, 2024
Real-world service costs for neovascular-AMD clinics in the United Kingdom: structured literature review and scenario analysisSobha Sivaprasad, Clare Bailey, Louise Downey, et al.
Pageof 10